Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations.

Kunlakanya JitobaomChompunuch BoonarkartSuwimon ManopwisedjaroenNuntaya PunyadeeSuparerk BorwornpinyoArunee ThitithanyanontPanisadee AvirutnanPrasert Auewarakul

Published in: BMC pharmacology & toxicology (2022)

The present study demonstrated the benefit of drug combinations on anti-SARS-CoV-2 activity. Niclosamide and ivermectin showed the best synergistic profile and should be further tested in clinical trials.

Keyphrases

sars cov
clinical trial
respiratory syndrome coronavirus
cancer therapy
emergency department
drug delivery
coronavirus disease
study protocol